 | |||||
| in | |||||
| NEWS | |||||
| Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III ... OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, ...
| |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
ShareThis
No comments:
Post a Comment